IC
DSGN icon

Ikarian Capital’s Design Therapeutics DSGN Stock Holding History

Ikarian Capital’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,568
Closed -$119K – 123
2022
Q4 		$119K Buy
+11,568
New +$157K 0.03% 77

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ikarian Capital's DSGN Position: Q1 2023 in Review

Ikarian Capital sold out of Design Therapeutics (DSGN) in Q1 2023, closing a stake of 11,568 shares — an estimated $119K sold.

Ikarian Capital first reported a position in DSGN in Q4 2022 and held it in 1 quarter. The position peaked at $119K in Q4 2022. 96 funds tracked by Wall St. Rank hold DSGN as of Q1 2023.

  • Ikarian Capital reported no remaining Design Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ikarian Capital sold 11,568 Design Therapeutics shares in Q1 2023, an estimated $119K.
  • Ikarian Capital first reported a position in Design Therapeutics in Q4 2022 and held it in 1 quarter.
  • Ikarian Capital's Design Therapeutics position peaked at $119K in Q4 2022.
  • 96 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2023.

Based on Ikarian Capital's 13F filing for Q1 2023, filed 15 May 2023.